Lately, a newly synthesized triazolo–thiadiazoles (4-MMI) has been shown to successfully inhibit enzymatic heparanase activity and heparanase-mediated VEGF gene expression, restraining the ability of carcinoma cells to extravasate through the subendothelial basement membrane. Here, HPSE is linked to carcinoma.